A clear, evidence-based value proposition that includes payers, patients, and healthcare providers (HCPs) is necessary to optimize access and reimbursement for novel healthcare interventions in the current and evolving healthcare landscape. The pharmaceutical and biotechnology sectors have always placed the greatest emphasis on the informational requirements of HCPs and patients, and they are now making significant progress in payer communications. However, there is still room for improvement in the industry when it comes to creating a unified, long-lasting communication plan that accounts for the variety of stakeholders in health technology assessment and payer decisions in the context of local, regional, and market concerns. Payer preferences are still changing, just like those of HCPs and patients. Producing high-quality safety and efficacy data is necessary, but it is not sufficient to demonstrate comprehensive clinical, humanistic, or economic value. Payers, patients, and HCPs all have distinct expectations; therefore, evidence of value needs to be packaged and delivered in accordance with their views and needs.
Why should you download this whitepaper?
Download this whitepaper to learn:
- Why driving high-value HEOR content is key to payer engagement
- Why understanding the needs of payers and contextualizing clinical and real-world data for specific payer customers are important
- Why payer-specific tailoring of professional and scientific communication is crucial
- How Cactus Life Sciences’ HEOR/payer-focused offerings and services, such as scientific payer communication plans including publications, interactive and virtual support tools with visually appealing formats, and field medical engagement tools, are improving value communications